 |
20 Diseases |  |
6 Trials |
|
6 Trials |  |
1040 News |  |
| «12...45678910111213141516» |
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: Xydalba Utilization Registry in France (clinicaltrials.gov) - Jul 20, 2021
P=N/A, N=151, Completed, Sponsor: Correvio International Sarl
Active, not recruiting --> Completed
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. (Pubmed Central) - Jul 17, 2021
Active, not recruiting --> Completed Dalbavancin use was associated with lower 90-day IRR, a shorter hospital LOS prior to therapy, and longer time-to-IRR compared with SOC.
- |||||| Zeven (dalbavancin) / RaQualia, AbbVie
New trial: Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) (clinicaltrials.gov) - Jul 12, 2021
P, N=100, Not yet recruiting, Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
- | Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019. (Pubmed Central) - Jul 8, 2021
All isolates were susceptible to dalbavancin. Dalbavancin MIC values remained stable for Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group since its clinical approval.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Review, Journal: Efficacy and Safety of Dalbavancin in Treatment of Gram-positive Bacterial Infections. (Pubmed Central) - Jul 7, 2021
Dalbavancin was comparable to other antibiotics in treating chronic Gram-positive bacterial infections in terms of efficacy and safety. The dual-dose regimen showed a better safety profile compared with the single-dose regimen in the treatment of skin infections.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. (Pubmed Central) - Jul 7, 2021
Dalbavancin inhibited >99.9% and 99.1% of isolates at the US FDA and EUCAST breakpoints, respectively. Clinical studies of dalbavancin for treatment of CoNS infections should be considered based on thesein vitro data.
- | Lamprene (clofazimine) / Novartis
Preclinical, Journal: In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens. (Pubmed Central) - Jul 7, 2021
Clinical studies of dalbavancin for treatment of CoNS infections should be considered based on thesein vitro data. In vitro activity was demonstrated for clofazimine, bedaquiline and eravacycline, indicating potential for inclusion as standardized therapy for M. abscessus complex infections.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus Causing Pneumonia in Patients with and without Cystic Fibrosis. (Pubmed Central) - Jul 7, 2021
Among MRSA isolates from CF/non-CF patients (n = 99/208), susceptibility to ceftaroline, clindamycin, levofloxacin, and tetracycline were 91.9%/93.3%, 58.6%/64.4%, 40.4%/29.3%, 83.8%/89.4%, respectively. Dalbavancin demonstrated high potency against S. aureus from CF and non-CF patients and may represent a valuable treatment option for CF patients with MRSA pulmonary infection.
- || Review, Journal: Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. (Pubmed Central) - Jul 4, 2021
Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol...Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Review, Journal: Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. (Pubmed Central) - Jul 3, 2021
Our study and literature data suggest that the use of dalbavancin in PJI could be considered, even in salvage therapy. Dalbavancin appears to be a safe and easy treatment for patients with staphylococcal PJIs.
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
If no OPAT then Dalbavancin 1500mg day 1 and 7 with surveillance cultures. Based on (Twitter) - Jul 2, 2021
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema. (Pubmed Central) - Jun 30, 2021
Dalbavancin appears to be a safe and easy treatment for patients with staphylococcal PJIs. No abstract available
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections. (Pubmed Central) - Jun 30, 2021
Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Dalvance the hell out of me. I can’t remember to take a a daily multivitamin so 5 weeks of SMX/TMP is going to be painful. (Twitter) - Jun 28, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Reimbursement: My guess is the hospital is paying for it and that they won’t be compensated for that loss. When I use dalbavancin in my clinic the patient pays for some and insurance pays for most and ultimately we all pay with higher insurance premiums. (Twitter) - Jun 28, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Mostly white middle age nonobese males. In your opinion, what are the limitations of dalbavancin treatment for OM @BradSpellberg @wfwrighID @DrToddLee @Cortes_Penfield @AntibioticDoc @SAIRABT @Darcy_ID_doc @IDDocJen @DocWoc71 @zchagla @TorontoIDDoc @maudi_ahmed @SuperBugDoc (Twitter) - Jun 28, 2021
- | Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. (Pubmed Central) - Jun 26, 2021
Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment. These studies demonstrate a major association between membrane remodelling, cross-resistance and the seesaw effect.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection. (Pubmed Central) - Jun 26, 2021
Although there was a marked decrease in cfu number, signs of biofilm-induced infection prevailed after 14 days of treatment. Further studies should be carried out to evaluate the potential of dalbavancin in the treatment of bone and orthopaedic implant-associated MRSA infections.
- | Journal: Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights. (Pubmed Central) - Jun 26, 2021
Of interest, the impact of susceptibility tests (in terms of MIC plates and their surface area) on the synergistic activity in 24 h time-kill experiments was apparent for LGPs. Further clinical research is required to investigate synergy with LGP/GPs and β-lactams against these Staphylococcus strains.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Dalbavancin for the management of osteomyelitis: a major step forward? (Pubmed Central) - Jun 23, 2021
However, information on the effectiveness and safety of dalbavancin in the treatment of invasive Gram-positive infections, such as osteomyelitis, is very limited. In this review, we describe the novel characteristics and potential utility of dalbavancin in the treatment of osteomyelitis and summarize its long-term clinical outcomes from published case reports, series and comparative studies.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: In vitro study to evaluate the bioactivity of freezing a heparin-based dalbavancin lock solution. (Pubmed Central) - Jun 22, 2021
AntiXa values (mean [SD] IU/ml) for heparin in combination with dalbavancin were within 25% of the heparin-water value.Conclusion. A heparin-based dalbavancin lock solution can be frozen for up to 6 months with no effect on its bioactivity against MRSA and MRSE biofilms.
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Dalbavancin compared to standard of care for outpatient treatment of confirmed or suspected invasive methicillin-resistant Staphylococcus aureus infections in people who inject drugs () - Jun 10, 2021 - Abstract #ECCMID2021ECCMID_4233;
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: Osteoarticular infection due to dalbavancin-resistant Staphylococci: Description of two cases. (Pubmed Central) - Jun 10, 2021
A heparin-based dalbavancin lock solution can be frozen for up to 6 months with no effect on its bioactivity against MRSA and MRSE biofilms. No abstract available
- Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie, cerulenin / Fermentek
[VIRTUAL] Alteration Of Lipid Metabolism And Resistance Phenotype To Cell Envelope-antimicrobials In Staphylococcus Aureus Via Fasii Inhibitors () - Jun 9, 2021 - Abstract #WMF2021WMF_5692;
The exception lied in cardiolipins (CLs) in the presence of AFN, where the fatty acid composition shifted to shorter chains in S7, but overall CL levels increased in S7-D2, suggesting that CL synthase was activated with exposure to AFN. Exposure to half-MIC of CER, AFN, and TRI did not reduce the MICs of VAN, DAP, or DAL.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. (Pubmed Central) - Jun 4, 2021
In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Retrospective data, Journal: Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. (Pubmed Central) - Jun 2, 2021
We also examine published experience of osteoarticular infection with special attention to DAL and PJI. In this experience, the use of dalbavancin contributed to shorten LOS and treatment-related costs, especially in difficult Gram-positive infections requiring prolonged therapy.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, PK/PD data, Journal: Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. (Pubmed Central) - Jun 1, 2021
In this experience, the use of dalbavancin contributed to shorten LOS and treatment-related costs, especially in difficult Gram-positive infections requiring prolonged therapy. A 3-compartment distribution model with first-order elimination provided an appropriate fit, with typical dalbavancin clearance of 0.05 L/h and total volume of distribution of ∼15 L. Impact of intrinsic factors was modest, although statistically significant (P 99% of subjects would achieve the nonclinical target at MIC values up to and including 2 mg/L.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases. (Pubmed Central) - Jun 1, 2021
A 3-compartment distribution model with first-order elimination provided an appropriate fit, with typical dalbavancin clearance of 0.05 L/h and total volume of distribution of ∼15 L. Impact of intrinsic factors was modest, although statistically significant (P 99% of subjects would achieve the nonclinical target at MIC values up to and including 2 mg/L. No abstract available
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Review, Journal: Current trends in the real life use of Dalbavancin: report of a study panel. (Pubmed Central) - May 28, 2021
In this review, we aimed at highlighting our experience with the use of Dalbavancin for some of the most hard-to-treat gram-positive infections, as well as a promising strategy in terms of pharmaco-economic effectiveness. We describe our current real life clinical practice with the use of Dalbavancin, depicting a few representative clinical cases in order to share our own practice in the hospital setting.
- || Zeven (dalbavancin) / RaQualia, AbbVie
Clinical, Journal: The Use of Dalbavancin with a Dermal Substitute Application - a Case Report. (Pubmed Central) - May 27, 2021
Multiple infectious complications in the skin and soft tissues with a high risk of development of phlebitis and with significant intolerance to a variety of antimicrobials were observed. The dramatic SSTI was treated using intravenous administration of dalbavancin, a very potent bactericidal antibiotic representing a rational option in the treatment of SSTIs caused by gram-positive bacteria.
- || Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Treatment of osteoarticular, cardiovascular, intravascular catheter-related, and other complicated infections with dalbavancin and oritavancin: a systematic review. (Pubmed Central) - May 20, 2021
This review provides evidence that laLGPs are safe and efficacious for osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections. Further research is needed to confirm these results.
- || Arbelic (telavancin) / Cumberland, Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Dalbavancin and Telavancin in the treatment of infective endocarditis: a literature review. (Pubmed Central) - May 20, 2021
Recent evidence has also emerged to support their use in the treatment of bone and joint infections. This article reviews the current literature on dalbavancin and telavancin in the treatment of infective endocarditis, a condition for which the role of these agents is yet to be established.
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Retrospective effectiveness study of dalbavancin and other standards of care of the same class (IV lipo- and glyco-peptides) in patients with acute bacterial skin and skin structure infections (ABSSSI): preliminary data analysis () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3294;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Dalbavancin in combination with a broad-spectrum ß-lactam for probabilistic treatment of infection or suspected periprosthetic hip or knee infection () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3240;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Dalbavancin in real clinical practice in Spain: a two-year retrospective study () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2985;
Dalbavancin seems to be effective and safe even as second-line treatment in severe infections caused by Gram-positive pathogens . Dalbavancin improves adherence and allows outpatients management.
- Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie, Zeftera (ceftobiprole) / Basilea
[VIRTUAL] In vitro activity of ceftobiprole and dalbavancin against a collection of daptomycin-, linezolid-, vancomycin- and/or teicoplanin-resistant coagulase-negative staphylococci isolates from clinical samples () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2909;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] In vitro activity of dalbavancin and other anti-staphylococcal agents against infecting isolates of methicillin-resistant coagulase-negative staphylococci () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2905;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Determination of a dalbavancin epidemiological cut-off value (ECOFF) for Enterococcus faecium () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2893;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Dalbavancin activity against biofilm-growing MRSA isolated from patients with complicated skin and soft tissue infections () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2394;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Pharmacokinetics of dalbavancin using 1g every 2 weeks for bone and joint infections () - May 20, 2021 - Abstract #ECCMID2021ECCMID_2249;
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Real-life pharmaco-economic analysis of Dalbavancin () - May 20, 2021 - Abstract #ECCMID2021ECCMID_1705;
- || Zeven (dalbavancin) / RaQualia, AbbVie
Very strange R pattern for a strep intermedius. Linezolid would be my choice here esp. If vancomycin would need q8 dosing to be therapeutic. Also when does dalbavancin for problematic streptococci enter this conversation 🤔😜? (Twitter) - May 19, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: REAL-DAL: Dalbavancin in Real Clinical Practice in Spain (clinicaltrials.gov) - May 17, 2021
P=N/A, N=187, Completed, Sponsor: Angelini Farmac
Dalbavancin improves adherence and allows outpatients management. Recruiting --> Completed
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Clinical: I don't disagree, often IV abx not an option. Pts who use drugs may leave prematurely (20-30%), & we should leave recs to account for that: "cont X antibiotics & if pt leaves sooner, pls send with Y po regimen + narcan." I like dalbavancin but some not willing to wait for it. (Twitter) - May 15, 2021
- |||| Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
Clinical: Sometimes that’s how we roll. I like dalbavancin or oritavancin as well since you don’t have to worry about patient taking it. I would consider linezolid assuming no contraindications ($70 14d). Best answer is talking to patient, they may need I&D. (Twitter) - May 14, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Clinical: Let me get some context. Patient is deep in Eastern KY in a small hospital. She did not want to stay for the hospital transfer that might take another 5 days, no dalbavancin in the Appalachian mountains. Patient was going to leave AMA and OSH provider did not want to place a PICC (Twitter) - May 14, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Clinical: Eh, POET had patients with MSSA and they did ok with PO and close outpatient followup, which is what you recommended. I wouldn’t do this myself but in part because I have the luxury of using dalbavancin p much whenever / in whomever I please. (Twitter) - May 14, 2021
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion, Trial completion date, Trial primary completion date: REDS: Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI (clinicaltrials.gov) - May 12, 2021
P=N/A, N=184, Completed, Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Recruiting --> Completed Recruiting --> Completed | Trial completion date: Oct 2020 --> May 2021 | Trial primary completion date: Oct 2020 --> May 2021
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] Evaluation of Patient Characteristics and Outcomes of Patients Treated with Dalbavancin for Bloodstream Infections (Poster Hall) - May 9, 2021 - Abstract #WMF2021WMF_2990;
The median (IQR) duration of bacteremia for the index culture was 49 hours (30.7-130) among 42 patients with available data, and 96% of patients received vancomycin prior to DAL initiation. In this small cohort of patients, DAL shows promise for further research as a long-acting antibiotic for Gram-positive BSI as a step-down therapy for discharge.
- Zeven (dalbavancin) / RaQualia, AbbVie
[VIRTUAL] In vitro activity of dalbavancin against glycopeptide-resistant Enterococcus faecium and coagulase-negative staphylococci recovered from patients in Germany () - May 8, 2021 - Abstract #ECCMID2021ECCMID_1076;
Further, DAL inhibited about 70% of the TRCoNS (even 87% of S . epidermidis) at the EUCAST breakpoint of 0.125 mg/L, and >96% at the CLSI breakpoint of 0.25 mg/L.